News

ViiV's Cabenuva is administered every two months and was offered to HIV patients who achieved viral suppression from daily treatments.
The timing of the exposure during pregnancy made a big difference in the level of risk associated with developing an allergic condition.
MSD unveiled the launch of the Phase III trials of MK-8527 at the International AIDS Society (IAS) 2025 conference.
AstraZeneca has reported positive outcomes from the BaxHTN Phase III trial of the highly selective ASI, baxdrostat.